eHI Complimentary Webinar on SDOH Impact on Equity and Diversity in Clinical Trials
January 12
1:00 p.m. EST

PRESS RELEASE
Contact: Courtney Watson
Phone: 202-624-3270
E-mail: courtney@ehidc.org
Website: www.ehidc.org/

WASHINGTON, DC USA -- HEALTHCARE UPDATE NEWS SERVICE™ -- DECEMBER 28, 2020: The FDA reports that only five percent of clinical trial participants are Black, fewer than two percent are Asian, and fewer than one percent are Hispanic or Latino. This gross underrepresentation in clinical research means that current treatments may not be equally safe and effective for all populations. This issue is also at the forefront of COVID vaccine distribution discussions as The COVID Tracking Project reports that Black people are 1.7 times more likely to die of COVID-19 than white people - more than 50,000 so far. Following them, American Indian/Alaskan Native and Hispanic or Latino.

On January 12, eHI will convene leading pharma manufacturers and leaders in public health to discuss current steps being taken to enhance diversity in clinical trials and to address the use of SDOH in their design.

Areas of discussion will include:

  • Research from studies that reveals how SDOH may have an impact on clinical trials
  • The implications of clinical trials without diversity, equity, or inclusion
  • Current pharma-led initiatives around health equity and diversity in clinical trials
  • Methods for ensuring SDOH is considered during vaccine development for infectious diseases, including COVID-19
SPEAKERS:

Jennifer Covich Bordenick
Chief Executive Officer, eHealth Initiative & Foundation

Luther T Clark, MD, FACC, FACP
Deputy Chief Patient Officer & Global Director, Scientific, Medical and Patient Perspective, Office of the Chief Patient Officer, Merck

Dana Dornsife
Founder and CEO Lazarex Cancer Foundation

Lili Gil Valletta
Co-Founder and CEO, CIEN+ and CulturIntel

Lorena Kuri
Diversity Strategy | Global Clinical Trial Planning & Alliances, Bristol Myers-Scribb

SUPPORT BY:

FOLLOW US ON SOCIAL MEDIA: